Enliven seeks its reverse merger payday
Early data with ELVN-001 hold up well against olverembatinib and TERN-701.
Another TIGIT bites the dust
GSK and iTeos dump belrestotug, with the latter now looking at “strategic alternatives”.
CytomX's EpCAM pivot does the job
After earlier masked probody setbacks, CytomX surprises with CX-2051.
Like Crest, Potomac succeeds up to a point
Imfinzi hits on disease-free survival, but BCG won't be displaced.
Revolution gets selective
The group’s latest update focused on new data with the KRAS G12C inhibitor elironrasib.
Takeda says no to B7-H3
TAK-280 is among the group's discarded projects, although it’s a T-cell engager, not an ADC.
Lantheus calls time on me-too Pluvicto
Final survival analysis draws a blank, and Lantheus throws in the towel.
